Twist Bioscience ( (TWST) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Twist Bioscience shares slipped as investors focused on a bearish analyst note that downplayed the strategic value of the company’s new Lilly TuneLab collaboration. While some on Wall Street see upside, the skeptical call argued the deal adds little to Twist’s long-term growth story, souring sentiment and pushing the stock lower.
The mixed analyst reaction did include some firms lifting their price targets, signaling that not all observers agree on the near‑term risk‑reward for the stock. Still, the louder message for traders today is that at least one influential voice remains firmly negative despite the headline‑grabbing partnership news.
Looking beyond today’s drop, Twist’s long record of revenue growth suggests its DNA synthesis and related tools are gaining steady traction with customers, which could help the business scale and eventually improve profitability. However, the company is still losing money and burning cash, so if it can’t rein in costs or turn that growth into solid earnings, it may need more funding and could struggle to hit its long‑term financial goals.
More about Twist Bioscience
YTD Price Performance: 546.28%
Average Trading Volume: 1,831,147
Technical Sentiment Signal: Buy
Current Market Cap: $12.42B
For further insights into TWST stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.
This story was written using TipRanks's AI tools and reviewed by a TipRanks editor.